Multiomics analysis of homologous recombination deficiency across cancer types
Biomolecules and Biomedicine · 2024
DOI: 10.17305/bb.2024.10448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2024. Verfasst von Lin Dong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Neoplasms, Homologous Recombination. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
There remains ongoing debate regarding the association of homologous recombination deficiency (HRD) with patient survival across various malignancies, highlighting the need for a comprehensive understanding of HRD's role in different cancer types. Based on data from databases, we conducted a multivariable omics analysis on HRD in 33 cancer types, focusing mainly on 23 cancers in which HRD was significantly associated with patient overall survival (OS) rates. This analysis included the mechanisms related to patient prognosis, gene expression, gene mutation, and signaling pathways. In this study, HRD was found to be significantly associated with patient prognosis, but its impact varied among different cancers. HRD was linked to different outcomes for patients with distinct tumor subtypes and was correlated with clinical features such as clinical stage and tumor grade. Driver gene mutations, including TP53, MUC4, KRAS, HRAS, FLG, ANK3, BRCA2, ATRX, FGFR3, NFE2L2, MAP3K1, PIK3CA, CIC, FUBP1, ALB, CTNNB1, and MED12, were associated with HRD across specific cancer types. We also analyzed differentially expressed genes (DEGs) and differentially methylated regions (DMRs) in relation to HRD levels in these cancers. Furthermore, we explored the correlation between HRD and signaling pathways, as well as immune cell infiltration. Overall, our findings contribute to a comprehensive understanding of HRD's multifaceted role in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.
- Department of Pathology, Tongling People's Hospital, Tongling, Anhui, China.
- Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China; Department of Pathology, Anhui Provincial Children's Hospital, Hefei, Anhui, China.
- Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.
- Department of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China; The CAS Key Laboratory of Innate Immunity and Ch…
- Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China; Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Zitieren
APA
Dong, L., Li, L., Zhu, L., Xu, F., Zhang, R., Li, Q., Zhu, Y., Zeng, Z., & Ding, K. (2024). Multiomics analysis of homologous recombination deficiency across cancer types. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2024.10448
Vancouver
Dong L, Li L, Zhu L, Xu F, Zhang R, Li Q, et al. Multiomics analysis of homologous recombination deficiency across cancer types. Biomolecules and Biomedicine. 2024. doi:10.17305/bb.2024.10448
BibTeX
@article{Dong2024,
author = {Dong, Lin and Li, Lin and Zhu, Linyan and Xu, Fei and Zhang, Rumeng and Li, Qiushuang and Zhu, Yong and Zeng, Zhutian and Ding, Keshuo},
title = {Multiomics analysis of homologous recombination deficiency across cancer types},
journal = {Biomolecules and Biomedicine},
year = {2024},
doi = {10.17305/bb.2024.10448}
}
EUVIMED